Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 3
Submit an article Journal homepage
152
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study

Oliver G. Ottmanna Department of Haematology, Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9559-1330View further author information
ORCID Icon,
Frank Stegelmannb Klinik für Innere Medizin III, Universitätsklinikum Ulm, Ulm, GermanyView further author information
,
Massimo Brecciac Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, ItalyORCID Iconhttps://orcid.org/0000-0003-1163-6162View further author information
ORCID Icon,
Juan Luis Steegmannd Instituto de Investigación Sanitaria, IIS-IP. Servicio de Hematología, Hospital Universitario de la Princesa, Madrid, SpainView further author information
,
Eduardo Olavarriae Servicio de Hematologia, Hospital de Navarra, Pamplona, SpainView further author information
,
Paola Aimonef Novartis Pharma AG, Basel, SwitzerlandView further author information
&
Jeffrey H. Liptong Princess Margaret Cancer Centre, Toronto, CanadaView further author information
 show all
Pages 739-742 | Received 19 May 2020, Accepted 15 Oct 2020, Published online: 06 Nov 2020

References

  • Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation. Cancer Cell. 2008;14(3):238–249.
  • Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119(6):1501–1510.
  • Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. 2009;458(7239):776–779.
  • Dao KH, Tyner JW. Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies. Clin Cancer Res. 2013;19(6):1309–1311.
  • Katagiri S, Tauchi T, Okabe S, et al. Combination of ponatinib with hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clin Cancer Res. 2013;19(6):1422–1432.
  • Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129–141.
  • Nilotinib. Novartis Pharmaceuticals Corporation Tasigna (Nilotinib) prescribing information. [cited 2014 Aug 25]. Available from: https://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf.
  • Irvine DA, Zhang B, Allan EK, et al. Combination of the Hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells. Blood. 2009;114(22):1428–1581.
  • Irvine DA, Zhang B, Kinstrie R, et al. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Sci Rep. 2016;6:25476.
  • Neuenschwander B, Matano A, Tang Z, et al. A Bayesian industry approach to Phase I combination trials in oncology. In: Zhao W and Yang H, editors. Statistical methods in drug combination studies. Boca Raton (FL): Chapman & Hall/CRC; 2014.
  • Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med. 2008;27(13):2420–2439.
  • Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17–23.
  • Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319–325.
  • Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–728.
  • Shah NP, Cortes JE, Martinelli G, et al. Dasatinib plus smoothened (SMO) inhibitor BMS-833923 in chronic myeloid leukemia (CML) with resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): Phase I Study CA180323. Blood. 2014;124(21):4539–4539.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.